BiotechTV

・

頻道・共 5 個節目

生命科學

生命科學

5月31日更新
生命科學

生命科學

6月25日更新
生命科學

生命科學

2月2日更新
生命科學

生命科學

3月5日更新
生命科學

生命科學

隔週更新

5月31日

ASCO 2026: Fresh off an IPO, Eikon Therapeutics Chairman & CEO Roger Perlmutter describes the scientific idea behind the company, and walks us through the leading programs

The lead two programs, which target TLR7/8 and PARP1, have data at ASCO and were licensed with the idea of laying the foundation for clinical expertise at Eikon. Another clinical program, a WRN helicase inhibitor, is the first to entirely come out of Eikon's platform. Plus, Dr. Perlmutter's take on being a public company, and his thoughts on China as a medicine cabinet to the world.
4月21日

Peter Hotez discusses tropical disease, the importance of science communication, career advice for young scientists, and more

He describes his work in tropical disease, and how climate change has been elevating it in areas like the Gulf Coast of the United States. Plus, the importance of elevating scientists, what he has found works best for communicating with the public, and why he disagrees with the idea of 'hunkering down' until a day that science funding might rebound in the U.S..
6月25日

Episode 7: Perceptive Advisors' Joe Edelman discusses how biotech investing has changed over his extensive career, and his thoughts on running an investment firm

He describes to Matt how the market has become more efficient since he started in the 1990's. He shares his perspective on single-asset vs pipeline companies, and today's M&A dynamic. Plus, his goal of being unbiased as an investor and how he tries to create an environment at Perceptive where that style is instilled in his analysts.
2025/11/03

Roche will pay Manifold Bio $55M up front, and up to $2B in biobucks, to collaborate on multiple next-generation brain shuttles for neurological diseases

Manifold Co-Founders Gleb Kuznetsov and Pierce Ogden explain how Manifold is working on next generation shuttles, which means going beyond transferrin. They discuss the deal, and also Manifold's broader platform of high-throughput, in-vivo discovery work.
2月19日

Cambridge, UK based Arecor uses formulation and development expertise to improve the profile of medicines - leveraging this, the company believes it has its own best in class insulin

CEO Sarah Howell discusses three key aspects of the business: helping with reformulation, its own proprietary insulin products, and developing oral peptides like GLPs.
2025/07/24

AI x Bio Summit: Recursion's Chief R&D Officer & CCO Najat Khan describes how the company leverages AI - including in both the dry lab and the wet lab, and all through clinical trials

She describes Recursion's work, and what the acquisition of Exscientia has brought to the company. Plus, how AI can not only help with drug design, but also safety and patient recruitment.
5月4日

Episode 39: SV Health Investors' Kate Bingham

Kate Bingham describes her early life and a serendipitous opportunity to work at Vertex in the early 1990's. She then discusses joining SV Health and describes its investment approaches, the Dementia Discovery Fund, being on the UK's Vaccine Taskforce during Covid, and more.
2025/05/02

VERAXA Biotech, which is part of Switzerland's Xlife Sciences incubator, will be going public in the U.S. via a SPAC in Q4 of this year. The company uses an AND-gating technology for TCEs and ADCs.

Xlife Sciences CEO Oliver Baumann introduces us to the fund, which is publicly traded in Switzerland, while VERAXA CEO Christoph Antz describes the BiTAC AND-gating platform the company uses to improve on the precision of T-cell engagers and antibody-drug conjugates.
2025/06/18

Draig Therapeutics launched from stealth today with a total of $140M investments to tackle neuropsych conditions. Co-Founder & Executive Chair Ruth McKernan tells the backstory and why she is excited

An Operating Partner at SV Health Investors, she describes how the company came together after reaching out to Cardiff University Professors John Atack and Simon Ward. She highlights how unusual it is to have clinical proof of concept data already while raising a series A, and why she believes Draig will make a difference for patients.
2025/05/09

Biotech investor Christoph Broja of EQT Life Sciences discusses biotech in Europe and highlights portfolio companies Tubulis, Agomab Therapeutics, and PanTera

He describes the current environment for life sciences in Europe and how far it has come over the last ten years. Plus, his thoughts on the value of being local for uncovering opportunities, and the state of the capital markets.

BiotechTV covers the biotechnology sector through news, stories, podcasts, and educational videos.

網站

BiotechTV

熱門節目

ASCO 2026: Fresh off an IPO, Eikon Therapeutics Chairman & CEO Roger Perlmutter describes the scientific idea behind the company, and walks us through the leading programs

Peter Hotez discusses tropical disease, the importance of science communication, career advice for young scientists, and more

Episode 7: Perceptive Advisors' Joe Edelman discusses how biotech investing has changed over his extensive career, and his thoughts on running an investment firm

Roche will pay Manifold Bio $55M up front, and up to $2B in biobucks, to collaborate on multiple next-generation brain shuttles for neurological diseases

Cambridge, UK based Arecor uses formulation and development expertise to improve the profile of medicines - leveraging this, the company believes it has its own best in class insulin

AI x Bio Summit: Recursion's Chief R&D Officer & CCO Najat Khan describes how the company leverages AI - including in both the dry lab and the wet lab, and all through clinical trials

Episode 39: SV Health Investors' Kate Bingham

VERAXA Biotech, which is part of Switzerland's Xlife Sciences incubator, will be going public in the U.S. via a SPAC in Q4 of this year. The company uses an AND-gating technology for TCEs and ADCs.

Draig Therapeutics launched from stealth today with a total of $140M investments to tackle neuropsych conditions. Co-Founder & Executive Chair Ruth McKernan tells the backstory and why she is excited

Biotech investor Christoph Broja of EQT Life Sciences discusses biotech in Europe and highlights portfolio companies Tubulis, Agomab Therapeutics, and PanTera

簡介

BiotechTV

熱門節目

熱門單集

簡介